LLY

1,093.51

-3.35%↓

JNJ

225.48

-2.31%↓

ABBV

215.94

-1.07%↓

UNH

380.86

-0.12%↓

MRK

119.64

+0.1%↑

LLY

1,093.51

-3.35%↓

JNJ

225.48

-2.31%↓

ABBV

215.94

-1.07%↓

UNH

380.86

-0.12%↓

MRK

119.64

+0.1%↑

LLY

1,093.51

-3.35%↓

JNJ

225.48

-2.31%↓

ABBV

215.94

-1.07%↓

UNH

380.86

-0.12%↓

MRK

119.64

+0.1%↑

LLY

1,093.51

-3.35%↓

JNJ

225.48

-2.31%↓

ABBV

215.94

-1.07%↓

UNH

380.86

-0.12%↓

MRK

119.64

+0.1%↑

LLY

1,093.51

-3.35%↓

JNJ

225.48

-2.31%↓

ABBV

215.94

-1.07%↓

UNH

380.86

-0.12%↓

MRK

119.64

+0.1%↑

Kodu・Aktsiate loetelu・Fate Therapeutics Inc

Fate Therapeutics Inc

Avatud

SektorTervishoid

2.75 10.89

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

2.46

Max

2.8

Põhinäitajad
By Trading Economics
Sissetulek	1.2M -31M
Müük	-70K 1.3M
Aktsiakasum	-0.26
Kasumimarginaal	-2,402.848
Töötajad	161
EBITDA	12M -30M

Soovitused
By TipRanks
Soovitused	Osta
12 kuu keskmine prognoos	+86.5% upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	10. aug 2026

Turustatistika
By TradingEconomics
Turukapital	8.8M 262M
Eelmine avamishind	-8.14
Eelmine sulgemishind	2.75

Uudiste sentiment

By Acuity

50%

156 / 344 Pingereas Healthcare

Fate Therapeutics Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

28. mai 2026, 22:47 UTC

Tulu

Costco 3Q Sales Rise as Value Offerings Draw Pressured Consumers -- Update

28. mai 2026, 20:45 UTC

Tulu

Costco 3Q Profit Rises as Value Offerings Draw Pressured Consumers

28. mai 2026, 23:43 UTC

Market Talk

Nikkei May Rise on Hopes for U.S.-Iran Peace Deal -- Market Talk

28. mai 2026, 23:39 UTC

Market Talk

Gold Edges Lower as Traders Assess Potential U.S.-Iran Deal -- Market Talk

28. mai 2026, 23:31 UTC

Market Talk

KMD Could Realize Value From Selling Either Oboz or Rip Curl -- Market Talk

28. mai 2026, 23:17 UTC

Market Talk

Mainfreight Steering Its Way Out of Tough Period -- Market Talk

28. mai 2026, 23:02 UTC

Market Talk

Costco Has Started Submitting Tariff Refund Claims -- Market Talk

28. mai 2026, 22:41 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

28. mai 2026, 22:41 UTC

Market Talk

MongoDB Still Getting More Growth From Established Customers Than AI -- Market Talk

28. mai 2026, 22:37 UTC

Market Talk

Omandamised, ülevõtmised, äriostud

M&A-Related Insurance Payments In North America Rise -- Market Talk

28. mai 2026, 22:04 UTC

Omandamised, ülevõtmised, äriostud

CN: Surface Transportation Board Was Right to Freeze the UP-NS Merger and Demand More Info

28. mai 2026, 22:04 UTC

Omandamised, ülevõtmised, äriostud

CN: This Confirms What CN and Many Stakeholders Have Said All Along, UP and NS Still Have Not Submitted a Credible Case to Support Their Proposed Merger >CNI

28. mai 2026, 21:12 UTC

Tulu

Omandamised, ülevõtmised, äriostud

Synopsys Was the Worst S&P 500 Stock Thursday Despite Earnings Beat With AI and Merger in Focus -- Barrons.com

28. mai 2026, 21:00 UTC

Tulu

Dell Stock Soars on Blowout Earnings. The Outlook Bests Analysts by $20 Billion. -- Barrons.com

28. mai 2026, 20:57 UTC

Tulu

Dell Stock Soars on Blowout Earnings -- Barrons.com

28. mai 2026, 20:55 UTC

Tulu

Costco Wholesale Sees a Mixed Quarter, Misses Earnings Estimates -- Barrons.com

28. mai 2026, 20:50 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

28. mai 2026, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

28. mai 2026, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

28. mai 2026, 20:48 UTC

Kuumad aktsiad

Stocks to Watch Recap: Snowflake, Union Pacific, Hormel Foods -- WSJ

28. mai 2026, 20:34 UTC

Tulu

One of the S&P 500's Highest Dividends Looks Even Better Now -- Barrons.com

28. mai 2026, 20:31 UTC

Tulu

Li and XPeng Both Miss Earnings Estimates. One Chinese EV Maker's Stock Is Rising. -- Barrons.com

28. mai 2026, 20:28 UTC

Tulu

Best Buy's 5% Dividend Yield Looks Even Better After Earnings -- Barrons.com

28. mai 2026, 20:26 UTC

Tulu

Dell Stock Soars on Blowout Earnings -- Barrons.com

28. mai 2026, 20:20 UTC

Tulu

Costco 3Q Membership Fees $1.37B

28. mai 2026, 20:20 UTC

Tulu

Costco 3Q Net Sales $69.15B

28. mai 2026, 20:19 UTC

Tulu

Costco 3Q Adj Same-Store Sales, Which Excludes Impacts From Gas Prices and Foreign Exchange, Rose 6.6% >COST

28. mai 2026, 20:19 UTC

Tulu

Costco 3Q Adjusted Digitally-Enabled Sales Rose 20.8% >COST

28. mai 2026, 20:17 UTC

Tulu

Costco 3Q Digitally-Enabled Sales Rose 21.5% >COST

28. mai 2026, 20:17 UTC

Tulu

Costco 3Q Same-Store Sales Up 9.8% >COST

Võrdlus sarnastega

Hinnamuutus

Fate Therapeutics Inc Prognoos

Hinnasiht

By TipRanks

86.5% tõus

12 kuu keskmine prognoos

Keskmine 4.42 USD 86.5%

Kõrge 7 USD

Madal 2.2 USD

Põhineb 8 Wall Streeti analüütiku instrumendi Fate Therapeutics Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

8 ratings

Osta

Hoia

Müü

Põhineb 8 analüütiku instrumendi Fate Therapeutics Inc aktsia reitingul - viimase 3 kuu andmed.

Sentiment

By Acuity

156 / 344 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Fate Therapeutics Inc

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders. Its CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.